RU2764547C2 - Конъюгаты аналогов эксенатида с замедленным высвобождением - Google Patents

Конъюгаты аналогов эксенатида с замедленным высвобождением Download PDF

Info

Publication number
RU2764547C2
RU2764547C2 RU2018136200A RU2018136200A RU2764547C2 RU 2764547 C2 RU2764547 C2 RU 2764547C2 RU 2018136200 A RU2018136200 A RU 2018136200A RU 2018136200 A RU2018136200 A RU 2018136200A RU 2764547 C2 RU2764547 C2 RU 2764547C2
Authority
RU
Russia
Prior art keywords
optionally substituted
alkyl
peptide
exenatide
hydrogel
Prior art date
Application number
RU2018136200A
Other languages
English (en)
Russian (ru)
Other versions
RU2018136200A3 (OSRAM
RU2018136200A (ru
Inventor
Эрик Л. ШНАЙДЕР
Брайан ХЁРН
Джеффри К. ХЕНИЗ
Гари В. ЭШЛИ
Даниэл В. САНТИ
Original Assignee
ПРОЛИНКС ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ПРОЛИНКС ЭлЭлСи filed Critical ПРОЛИНКС ЭлЭлСи
Publication of RU2018136200A publication Critical patent/RU2018136200A/ru
Publication of RU2018136200A3 publication Critical patent/RU2018136200A3/ru
Application granted granted Critical
Publication of RU2764547C2 publication Critical patent/RU2764547C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
RU2018136200A 2016-03-16 2017-03-16 Конъюгаты аналогов эксенатида с замедленным высвобождением RU2764547C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662309330P 2016-03-16 2016-03-16
US62/309,330 2016-03-16
US201662416058P 2016-11-01 2016-11-01
US62/416,058 2016-11-01
PCT/US2017/022791 WO2017161174A1 (en) 2016-03-16 2017-03-16 Extended release conjugates of exenatide analogs

Publications (3)

Publication Number Publication Date
RU2018136200A RU2018136200A (ru) 2020-04-16
RU2018136200A3 RU2018136200A3 (OSRAM) 2020-12-25
RU2764547C2 true RU2764547C2 (ru) 2022-01-18

Family

ID=59852218

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018136200A RU2764547C2 (ru) 2016-03-16 2017-03-16 Конъюгаты аналогов эксенатида с замедленным высвобождением

Country Status (13)

Country Link
US (1) US20200164083A1 (OSRAM)
EP (2) EP3922269A1 (OSRAM)
JP (1) JP7017248B2 (OSRAM)
KR (1) KR20180129825A (OSRAM)
CN (1) CN109414469A (OSRAM)
AU (2) AU2017234680A1 (OSRAM)
BR (1) BR112018068639A2 (OSRAM)
CA (1) CA3016814A1 (OSRAM)
MX (1) MX2018011149A (OSRAM)
RU (1) RU2764547C2 (OSRAM)
SG (1) SG11201807832VA (OSRAM)
WO (1) WO2017161174A1 (OSRAM)
ZA (2) ZA201805953B (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10745456B2 (en) * 2015-04-01 2020-08-18 The Scripps Research Institute Methods and compositions related to GPCR agonist polypeptides
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
AR116566A1 (es) 2018-10-03 2021-05-19 Novartis Ag Administración sostenida de polipéptidos similares a la angiopoyetina 3
EP3946460A4 (en) 2019-04-05 2023-03-29 Prolynx LLC IMPROVED CONJUGATIONAL LINKERS
KR20220045975A (ko) * 2019-08-07 2022-04-13 프로린크스 엘엘시 베타-제거 링커에 의해 가교된 하이드로겔의 증기 멸균
JP2023550784A (ja) * 2020-11-25 2023-12-05 プロリンクス エルエルシー Ｃ－ナトリウム利尿ペプチドの徐放性ヒドロゲルコンジュゲート
WO2025128916A1 (en) * 2023-12-13 2025-06-19 Cellanome, Inc. Devices and methods for analyzing biological samples
KR102716759B1 (ko) 2023-12-20 2024-10-15 (주)인벤티지랩 엑세나타이드를 포함하는 서방형 주사제 조성물 및 이의 제조 방법

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004022004A2 (en) * 2002-09-06 2004-03-18 Bayer Pharmaceuticals Corporation Modified glp-1 receptor agonists and their pharmacological methods of use
WO2008116294A1 (en) * 2007-03-23 2008-10-02 Matregen Corp. Exendin analogs
US20110268807A1 (en) * 2008-08-04 2011-11-03 James Su Biodegradable Microspheres and Methods of Use Thereof
US20130116407A1 (en) * 2010-05-05 2013-05-09 Gary Ashley Controlled release from macromolecular conjugates
US20130123487A1 (en) * 2010-05-05 2013-05-16 Prolynx Llc Controlled release from solid supports
RU2573995C2 (ru) * 2009-11-13 2016-01-27 Санофи-Авентис Дойчланд Гмбх Фармацевтическая композиция, содержащая агонист гпп-1 и метионин

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0007823A8 (pt) * 1999-01-14 2017-03-21 Amylin Pharmaceuticals Inc Métodos de supressão do glucagon
WO2004035623A2 (en) 2002-10-02 2004-04-29 Zealand Pharma A/S Stabilized exendin-4 compounds
EP1845105A4 (en) * 2005-01-14 2009-02-18 Wuxi Grandchamp Pharmaceutical MODIFIED EXENDINES AND CORRESPONDING USES
GB2427360A (en) 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
CN102827284B (zh) * 2006-11-14 2015-07-29 上海仁会生物制药股份有限公司 带有聚乙二醇基团的Exendin或其类似物及其制剂和用途
WO2009158668A1 (en) 2008-06-26 2009-12-30 Prolynx Llc Prodrugs and drug-macromolecule conjugates having controlled drug release rates
EP2571496A4 (en) 2010-05-05 2016-03-30 Prolynx Llc CONTROLLED RELEASE OF MEDICINE FROM DENIMERS
US8263554B2 (en) * 2010-06-09 2012-09-11 Amylin Pharmaceuticals, Inc. Methods of using GLP-1 receptor agonists to treat pancreatitis
JP6158185B2 (ja) 2011-09-07 2017-07-05 プロリンクス エルエルシー 生分解性架橋を有するヒドロゲル
EP2768856A4 (en) * 2011-10-18 2015-05-27 Prolynx Llc PEG CONJUGATES OF EXENATIDE

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004022004A2 (en) * 2002-09-06 2004-03-18 Bayer Pharmaceuticals Corporation Modified glp-1 receptor agonists and their pharmacological methods of use
WO2008116294A1 (en) * 2007-03-23 2008-10-02 Matregen Corp. Exendin analogs
US20110268807A1 (en) * 2008-08-04 2011-11-03 James Su Biodegradable Microspheres and Methods of Use Thereof
RU2573995C2 (ru) * 2009-11-13 2016-01-27 Санофи-Авентис Дойчланд Гмбх Фармацевтическая композиция, содержащая агонист гпп-1 и метионин
US20130116407A1 (en) * 2010-05-05 2013-05-09 Gary Ashley Controlled release from macromolecular conjugates
US20130123487A1 (en) * 2010-05-05 2013-05-16 Prolynx Llc Controlled release from solid supports
US8946405B2 (en) * 2010-05-05 2015-02-03 Prolynx Llc Controlled release from solid supports

Also Published As

Publication number Publication date
US20200164083A1 (en) 2020-05-28
BR112018068639A2 (pt) 2019-07-30
ZA201805953B (en) 2019-11-27
CA3016814A1 (en) 2017-09-21
EP3922269A1 (en) 2021-12-15
ZA201905787B (en) 2021-03-31
AU2017234680A2 (en) 2018-12-13
AU2017234680A1 (en) 2018-10-11
JP2019511497A (ja) 2019-04-25
SG11201807832VA (en) 2018-10-30
EP3429608A4 (en) 2019-12-11
EP3429608A1 (en) 2019-01-23
AU2021232810A1 (en) 2021-10-14
KR20180129825A (ko) 2018-12-05
WO2017161174A1 (en) 2017-09-21
RU2018136200A3 (OSRAM) 2020-12-25
JP7017248B2 (ja) 2022-02-08
RU2018136200A (ru) 2020-04-16
CN109414469A (zh) 2019-03-01
MX2018011149A (es) 2019-05-30

Similar Documents

Publication Publication Date Title
RU2764547C2 (ru) Конъюгаты аналогов эксенатида с замедленным высвобождением
JP6931033B2 (ja) インスリン受容体部分アゴニスト
EP3922260A2 (en) Insulin receptor partial agonists and glp-1 analogues
KR20160075665A (ko) 소마토스타틴 및 그 유사체의 컨쥬게이트
HK40064590A (en) Extended release conjugates of exenatide analogs
NZ786229A (en) Extended release conjugates of exenatide analogs
US20240277816A1 (en) Polypeptide conjugate and application thereof in preparation of drug for treating diseases related to glucose metabolism
BR122024000898B1 (pt) Composto, composição, e, uso do composto
EA041034B1 (ru) Частичные агонисты инсулинового рецептора
BR122024000903B1 (pt) Composto, composição, e, uso do composto
BR112017010481B1 (pt) Composto útil como agonista parcial de receptor de insulina, composição, e, uso de uma composição